Home โบ Blood Cancers โบ Ohio
Blood Cancers clinical trials in Ohio
22 studies for Blood Cancers are looking for participants at sites in Ohio.
Cities in Ohio
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 8, Columbus
RecruitingPhase 3
Ages 18 to 71 ยท All sexes ยท Updated Sep 23, 2026 ยท NCT07504458Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT03816345Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 21, 2026 ยท NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Strecker Cancer Center-Belpre, Belpre
- Miami Valley Hospital South, Centerville
- Adena Regional Medical Center, Chillicothe
- and 27 more
RecruitingObservational study
All ages ยท All sexes ยท Updated Sep 17, 2026 ยท NCT04242095Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- and 44 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 ยท All sexes ยท Updated Sep 2, 2026 ยท NCT05334069A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Cincinnati, Cincinnati
- OhioHealth Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
RecruitingObservational study
Ages 0 and older ยท All sexes ยท Updated Sep 2, 2026 ยท NCT07154823Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- UH Seidman Cancer Center, Cleveland
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Aug 20, 2026 ยท NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Ohio State University, Columbus
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Aug 20, 2026 ยท NCT07007312A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Gabrail Cancer Center, Canton
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Aug 10, 2026 ยท NCT06823167Weighted Blanket Use to Reduce Anxiety in Oncology Patients
- Ohio State University Comprehensive Cancer Center, Columbus
Recruiting
Ages 18 and older ยท All sexes ยท Updated Aug 5, 2026 ยท NCT06089408A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Childrens Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital, Cincinnati
- University Hospitals Case Medical Center, Cleveland
- and 3 more
RecruitingObservational study
All ages ยท All sexes ยท Updated Jul 6, 2026 ยท NCT01351545Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingObservational study
Ages 0 to 38 ยท All sexes ยท Updated Jun 4, 2026 ยท NCT06131801Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
RecruitingPhase 1
Ages 13 and older ยท All sexes ยท Updated May 5, 2026 ยท NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Apr 16, 2026 ยท NCT03328078Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
- Ohio State University Comprehensive Cancer Center, Columbus
Recruiting
Ages 18 and older ยท All sexes ยท Updated Apr 9, 2026 ยท NCT05178472A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Taussig Cancer Institute, Cleveland
- The James Cancer Hospital and Solove Research Institute, Columbus
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Mar 13, 2026 ยท NCT05735184Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
- Gabrail Cancer Center, Canton
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Feb 11, 2026 ยท NCT07036133A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- University of Cincinnati Medical Center, Cincinnati
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Jun 25, 2025 ยท NCT05768269IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- University Hospitals Cleveland, Cleveland
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Jun 3, 2025 ยท NCT06119685ฮฑฮฒT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
- Nationwide Children's Hospital, Columbus
Recruiting
Up to age 30 ยท All sexes ยท Updated Apr 2, 2025 ยท NCT06082947Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies, Cleveland
- Nationwide Children's Hospital, Columbus
RecruitingPhase 1
Ages 1 to 21 ยท All sexes ยท Updated Dec 6, 2024 ยท NCT05476770Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Nov 15, 2024 ยท NCT06034275From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.